Those shares fell as Astra presented data on another pill that showed similar weight-loss benefits. Shares of obesity-shot makers Eli Lilly & Co. and Novo Nordisk A/S dipped, while Astra’s ...

LONDON, United Kingdom - AstraZeneca said on Monday its experimental weight-loss pill ... once-daily obesity pill from Eccogene a year ago for up to $2 billion, it said it believed the treatment could ...

Novo and Lilly are also working on oral weight loss drugs ... has another pill, amycretin. A phase 1 trial of amycretin released in September showed promising results. Meanwhile, Eli Lilly ...

Additionally, Eli Lilly and Company (NYSE ... which drives approximately 25% weight loss, and orforglipron, a daily pill that produces approximately 15% weight loss. In the U.S. alone, there ...

Novo Nordisk and Eli Lilly are also developing even more powerful weight-loss drugs. The majority of these companies are also working to introduce weight-loss pills. Weight-loss drugs that already ...

The obesity medicines market has so far been dominated by Novo Nordisk’s (NVO) Wegovy and Eli ... pill at the conference and that Lilly and Novo also have pills for weight loss in the works.

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for its experimental obesity pill ... Eli Lilly's (LLY) blockbuster weight ...

Oral GLP-1 drug in study led to average weight loss of 8.2% in a month at a 100 ... drugs popularized by Novo Nordisk (DK:NOVO.B) and Eli Lilly (LLY), although the existing drugs on the market ...

The Danish drugmaker’s arch-rival Eli Lilly & Co. has introduced another shot — Zepbound, also known as Mounjaro — that so far has shown even more weight loss than Wegovy. A pack of other companies ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked in traditional channels. An injection pen of Zepbound, Eli Lilly’s ...